TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference
Mar 17, 2017 11:30 am UTC| Business
NEW YORK, March 17, 2017 -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 27th Annual Oppenheimer Healthcare...
Origin Sciences’ OriCol™ to be used in HIV study
Mar 17, 2017 11:27 am UTC| Business
LONDON and CAMBRIDGE, United Kingdom, March 17, 2017 -- Fred Hutchinson Cancer Research Center (Fred Hutch) has selected Origin Sciences’ novel mucosal sampling device OriCol™ for use in sample collection as part of a...
Intelligent Systems Announces Fiscal Year 2016 Results
Mar 17, 2017 11:15 am UTC| Business
NORCROSS, Ga., March 17, 2017 -- Intelligent Systems Corporation (NYSE MKT:INS) announced today its financial results for the three and twelve month periods ended December 31, 2016. Revenue was $2,334,000 and...
Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data
Mar 17, 2017 11:05 am UTC| Business
SAN RAMON, Calif., March 17, 2017 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today announced the final analysis...
Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21
Mar 17, 2017 11:03 am UTC| Business
GERMANTOWN, Md., March 17, 2017 -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announces that Rich Daly,...
RLHC Integrates its Hello Rewards App with Concur to Simplify Business Travel
Mar 17, 2017 11:02 am UTC| Business
SPOKANE, Wash., March 17, 2017 -- RLHC (Red Lion Hotels Corporation) (NYSE:RLH) today announced the integration of the Hello Rewards app with Concur®, the leading provider of spend management solutions and services. Now...
Mar 17, 2017 11:01 am UTC| Business
- OBE022 is ObsEva's potential first-in-class, oral and selective PGF2alpha receptor antagonist - Geneva, Switzerland - 17 March 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the...